TGFB1 and neoplasm: However, preclinical data showed that the TGF-β inhibitor LY2157299, in combination with adoptive NK cell therapy, resulted in better tumor suppression than LY2157299 or NK cells alone in a mouse model for metastatic colon cancer [114].